DrugPatentWatch Database Preview➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing
« Back to Dashboard
Summary for Patent: 9,649,364
|Title:||Methods for producing stable therapeutic formulations in aprotic polar solvents|
|Abstract:||Certain embodiments are directed to a formulation of a therapeutic agent, as well as a method of making such a formulation, comprising at least one therapeutic agent dissolved in an aprotic polar solvent system comprising at least one ionization stabilizing excipient in a concentration sufficient to impart physical and chemical stability to the therapeutic agent.|
|Inventor(s):||Prestrelski; Steven (San Diego, CA), Sandoval; Michael (Austin, TX), Donovan; Martin (Austin, TX)|
|Assignee:||XERIS PHARMACEUTICALS, INC. (Austin, TX)|
1. A stable formulation comprising: (a) a glucagon peptide or salt thereof, wherein the glucagon peptide or salt thereof is not prepared by drying in the presence of a
non-volatile buffer having a pH of 2 to 4 to produce a glucagon peptide having a pH memory of 2 to 4; (b) an ionization stabilizing excipient; and (c) an aprotic polar solvent; wherein (i) the glucagon peptide or salt thereof is dissolved in the
aprotic solvent in an amount from about 0.1 mg/mL up to the solubility limit of the glucagon peptide or salt thereof, and (ii) the ionization stabilizing excipient is dissolved in the aprotic solvent in an amount to stabilize the ionization of the
glucagon peptide or salt thereof.
2. The formulation of claim 1, wherein the ionization stabilizing excipient is at a concentration of 0.1 mM to less than 100 mM.
3. The formulation of claim 1, wherein the ionization stabilizing excipient is a mineral acid.
4. The formulation of claim 3, wherein the mineral acid is hydrochloric acid (HCl).
5. The formulation of claim 1, wherein the aprotic solvent is dimethylsulfoxide (DMSO).
6. The formulation of claim 1, wherein the aprotic solvent is a deoxygenated aprotic solvent.
7. The formulation of claim 6, wherein the deoxygenated aprotic solvent is deoxygenated DMSO.
8. The formulation of claim 1, wherein the ionization stabilizing excipient is HCl and the aprotic solvent is DMSO.
9. The formulation of claim 1, wherein the moisture content is less than 10% (w/w).
10. The formulation of claim 1, further comprising a preservative at less than 10% w/v.
11. The formulation of claim 10, wherein the preservative is benzyl alcohol.
12. The formulation of claim 1, further comprising a sugar alcohol at less than 10% w/v.
13. The formulation of claim 12, wherein the sugar alcohol is trehalose.
14. A method of treating hypoglycemia in a subject in need thereof, the method comprising the step of administering an effective amount of the formulation of claim 1.
15. The method of claim 14, wherein the administering is by parenteral injection.
16. The method of claim 15, wherein the injection is intracutaneous injection.
Make Better Decisions: Try a trial or see plans & pricing
Serving leading biopharmaceutical companies globally:
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.